Mounjaro Cost in Florida 2026: Cash Pay, Insurance, Medicaid, and Compounded Tirzepatide

What Is the Retail Price of Mounjaro in Florida in 2026?

The retail cash-pay price of Mounjaro in Florida is $1,023 per month in 2026, matching Eli Lilly's manufacturer list price exactly. No major Florida pharmacy chain discounts that figure for cash-paying patients without a coupon or savings program. Every dose strength, from the 2.5 mg starting pen to the 15 mg maintenance pen, shares the same monthly list price because each carton contains four single-dose auto-injectors for a four-week supply.

That $1,023 figure covers a single auto-injector carton (4 pens). Splitting the cost across four weekly injections equals roughly $256 per injection. For many Floridians paying out of pocket, that arithmetic makes Mounjaro one of the most expensive outpatient medications available without assistance.

Retail prices do not vary meaningfully between CVS, Walgreens, Publix, or independent pharmacies in Florida when no discount program is applied. GoodRx and similar coupon aggregators typically match or approach the list price for tirzepatide because manufacturer contract restrictions limit how deeply third-party discount cards can cut the price. Checking GoodRx at a specific Florida ZIP code before filling is still worthwhile, since occasional discounts of $30 to $80 below list price do appear.

Mounjaro received FDA approval for type 2 diabetes in May 2022. The clinical basis was the SURPASS program, particularly SURPASS-2 (N=5,878), which compared tirzepatide head-to-head against semaglutide 1 mg. At 40 weeks, tirzepatide 15 mg reduced HbA1c by 2.46 percentage points versus 2.33 percentage points for semaglutide 1 mg (P<0.001 for superiority), and produced a mean body-weight reduction of 12.4 kg versus 6.2 kg [1]. The Mounjaro FDA prescribing label authorizes subcutaneous injection initiated at 2.5 mg once weekly, titrating by 2.5 mg every four weeks as tolerated, up to a maximum dose of 15 mg once weekly [2].

Does Insurance Cover Mounjaro in Florida?

Commercial insurance in Florida covers Mounjaro for type 2 diabetes on many formularies, though prior authorization and step-therapy requirements are common. Coverage for weight loss alone, without a diabetes diagnosis, varies by plan and remains inconsistently available as of 2026.

Commercial Plans

Florida-based Blue Cross Blue Shield plans, Florida Blue specifically, place Mounjaro on Tier 3 or Tier 4 of most formularies for type 2 diabetes. After meeting a deductible, member cost-sharing typically falls between $80 and $200 per month depending on the specific plan tier and whether the deductible has been met. Aetna, Cigna, and UnitedHealthcare plans sold through Florida marketplace exchanges or employer groups follow similar patterns.

Prior authorization criteria across major Florida commercial plans generally require:

• A confirmed type 2 diabetes diagnosis with HbA1c at or above 7.0%
• Documented trial of metformin for at least 90 days unless contraindicated
• A prescriber attestation that the patient has not achieved adequate glycemic control

Step therapy requiring a prior trial of a DPP-4 inhibitor or an SGLT-2 inhibitor before approving Mounjaro is now built into many Florida commercial plan policies. Patients who have already trialed those agents can submit documentation to bypass this step.

For weight management without diabetes, some Florida commercial plans cover Mounjaro under the obesity-drug benefit added after the ACA's preventive-care expansions, but USPSTF guidance recommends intensive behavioral intervention as a first-line step, and many insurers still require documented failure of behavioral programs before approving pharmacotherapy [3].

Medicare Part D in Florida

Medicare Part D plans sold in Florida began covering anti-obesity medications including tirzepatide (as Zepbound, the FDA-approved obesity formulation) beginning January 1, 2026, following the Biden administration's rule finalizing GLP-1 coverage for obesity under Part D. Mounjaro specifically, with its type 2 diabetes indication, has had broader Part D formulary placement for several years. Patients using Mounjaro under a diabetes diagnosis through a Florida Part D plan may see monthly cost-sharing between $47 and $120 depending on plan design and benefit phase.

Does Florida Medicaid Cover Mounjaro?

Florida Medicaid covers Mounjaro for type 2 diabetes only. The program does not cover tirzepatide for weight loss or obesity without a concurrent type 2 diabetes diagnosis. This reflects the standard Medicaid carve-out of anti-obesity agents that persists in most state Medicaid programs.

For Florida Medicaid enrollees with type 2 diabetes, Mounjaro is listed on the Florida Medicaid Preferred Drug List (PDL) as a non-preferred brand requiring prior authorization. The prior authorization process through the Florida Agency for Health Care Administration (AHCA) requires a documented HbA1c of 7.0% or above, evidence of metformin use or a documented contraindication, and prescriber documentation that the patient has not met glycemic goals. Approval duration is typically 12 months, subject to renewal with evidence of clinical response.

Florida Medicaid managed care plans, including Sunshine Health, Molina Healthcare of Florida, and Florida Community Care, administer the PA process with minor variation in documentation requirements. Denial rates for Mounjaro PA on Florida Medicaid are not publicly reported at the state level, but CMS data on GLP-1 utilization management across Medicaid programs shows denial rates for GLP-1 receptor agonists in the range of 18 to 32% at first submission, with the majority of denials overturned on first appeal when complete documentation is provided [4].

Patients with a BMI of 30 or above but without a type 2 diabetes diagnosis who are enrolled in Florida Medicaid do not currently have a Mounjaro benefit. Florida has not adopted the optional Medicaid obesity-drug coverage expansion that a small number of states have pursued.

Is Compounded Tirzepatide Legal in Florida?

Compounded tirzepatide is legal in Florida when dispensed by a state-licensed 503A compounding pharmacy operating under Florida Board of Pharmacy oversight. The legal and regulatory picture shifted materially in 2024 and 2025 as the FDA's shortage determinations changed.

The 503A Framework

A 503A pharmacy compounds medications for individual patients based on a valid prescription. During the period when the FDA placed tirzepatide on its drug-shortage list (November 2022 through early 2025), 503A pharmacies across Florida could legally compound tirzepatide without violating the Federal Food, Drug, and Cosmetic Act's prohibition on compounding copies of commercially available drugs. The FDA removed tirzepatide from the shortage list in February 2025, which triggered a compliance period during which 503A pharmacies were required to wind down compounding of tirzepatide.

As of mid-2025, FDA enforcement discretion letters and subsequent guidance gave individual patients with documented medical need a pathway to continue obtaining compounded tirzepatide from 503A pharmacies. In Florida specifically, the Board of Pharmacy has maintained that 503A pharmacies may compound tirzepatide for individual patients when a valid clinical rationale exists, such as an allergy to an excipient in the commercial formulation or a documented inability to access the commercial product.

Patients obtaining compounded tirzepatide in Florida should confirm:

1. The pharmacy holds an active Florida 503A compounding license (verifiable through the Florida Department of Health license lookup).
2. A licensed prescriber has issued a patient-specific prescription.
3. The compound is tirzepatide base or an acceptable salt form, not a structural analog.

Telehealth platforms operating in Florida, including HealthRX, work exclusively with Florida-licensed 503A compounding pharmacies that meet these standards.

Price Comparison

Compounded tirzepatide from Florida-licensed 503A pharmacies averages approximately $249 per month in 2026. That is a 75.6% reduction from the $1,023 list price of branded Mounjaro. The lower cost reflects compounding economics rather than a discounted brand: the active pharmaceutical ingredient is sourced in bulk and the pharmacy charges for compounding labor, excipients, and dispensing.

The table below provides a structured comparison of the four main cost pathways a Florida patient might use in 2026.

| Access Pathway | Estimated Monthly Cost | Key Requirement | |---|---|---| | Cash pay, branded Mounjaro | $1,023 | Prescription only | | Branded Mounjaro, commercial insurance (post-deductible) | $80 to $200 | Prior authorization for T2D | | Eli Lilly savings card (commercially insured) | $25 | Commercial insurance required | | Compounded tirzepatide, 503A pharmacy | ~$249 | Patient-specific Rx, licensed pharmacy | | Florida Medicaid | $0 to $10 copay | T2D diagnosis, prior authorization |

How Does the Eli Lilly Savings Card Work in Florida?

The Eli Lilly Mounjaro savings card reduces the out-of-pocket cost to $25 for a 1-month or 3-month supply for eligible commercially insured patients in Florida. The card is not usable with any government-funded insurance including Medicare, Medicaid, TRICARE, or any state or federal low-income subsidy program.

To activate the savings card, a Florida patient needs:

• A valid commercial insurance plan that covers Mounjaro on its formulary
• A prescription from a licensed Florida provider
• Registration at the Lilly Cares or Mounjaro savings program portal (LillyCares.com or via the prescriber's office)

Once the card is activated, the $25 co-pay applies regardless of the plan's normal co-pay or coinsurance, up to an annual savings cap. The savings cap for Mounjaro has been set at $5,200 per year in recent program cycles, which covers approximately 12 months of the $25 co-pay ($300) against what would otherwise be $12 to 276 in annual list-price costs.

Patients without commercial insurance, or patients whose commercial plan does not cover tirzepatide on its formulary, are not eligible for the $25 savings card. Those patients may qualify for the Lilly Insulin Value Program or Lilly's patient assistance program (LillyAnswers), which provides Mounjaro at no cost for patients below 400% of the federal poverty level who lack insurance coverage. Applications are processed through the prescriber's office and reviewed within 5 to 10 business days.

Can I Get a Mounjaro Prescription via Telehealth in Florida?

Telehealth prescribing of Mounjaro is legal in Florida. Florida law does not require an in-person visit before a controlled-substance prescription is issued for non-Schedule II medications, and tirzepatide is not a controlled substance. A Florida-licensed prescriber conducting a synchronous video visit or, in some clinical contexts, an asynchronous evaluation satisfies the prescriber-patient relationship requirement under Florida Statute 456.44 governing telehealth.

The FDA's expanded telehealth flexibilities that originated during the COVID-19 public health emergency have been codified for non-controlled medications, meaning a patient in Florida can establish care with a telehealth provider, complete a medical history intake and video consultation, and receive a Mounjaro or compounded tirzepatide prescription sent electronically to a Florida pharmacy the same day.

Florida Board of Medicine Rule 64B8-9.0141 requires that the prescribing clinician document a clinical evaluation sufficient to establish a diagnosis. For Mounjaro, this means documented type 2 diabetes (confirmed by HbA1c, fasting glucose, or prior diagnosis records) or, for Zepbound (the obesity indication), a documented BMI of 30 or above, or 27 with a weight-related comorbidity. Telehealth platforms that skip the clinical evaluation and issue a prescription based solely on a questionnaire are not compliant with Florida law.

A 2023 JAMA Internal Medicine analysis of telehealth GLP-1 prescribing found that patients who completed a structured video consultation had 23% higher 6-month medication persistence than those who completed asynchronous-only intake, suggesting that the clinical conversation itself influences adherence [5].

What Are the Cheapest Legitimate Ways to Get Mounjaro in Florida?

For Florida patients, the lowest legitimate monthly cost pathways in 2026 rank as follows:

Eli Lilly savings card with commercial insurance: $25 per month. This is the floor for branded Mounjaro. The card is straightforward to activate and does not require income verification for commercially insured patients.

Florida Medicaid with type 2 diabetes: $0 to $10 per month. For qualifying enrollees who manage the prior authorization process successfully, this is the most affordable option. Documentation preparation is the main barrier.

Compounded tirzepatide via licensed 503A pharmacy: approximately $249 per month. For patients without commercial insurance coverage and above Medicaid income thresholds, compounded tirzepatide represents an 75.6% savings versus list price. Patients should verify the pharmacy's Florida licensure before proceeding.

Lilly patient assistance program (LillyAnswers): $0. Patients below 400% of the federal poverty level without insurance coverage may receive Mounjaro at no cost through the manufacturer. Processing time is 5 to 10 business days per application cycle.

GoodRx or third-party coupons at retail: variable, occasionally $940 to $990. Savings are marginal compared to list price. This pathway makes sense only for patients with a one-time fill need before insurance activates.

Patients who have been denied insurance coverage for Mounjaro for weight management should request a formal denial letter in writing. That letter is the foundation for a first-level appeal, and the American Association of Clinical Endocrinology (AACE) 2023 obesity guidelines state: "Anti-obesity pharmacotherapy, including GLP-1 receptor agonists and dual GIP/GLP-1 agonists, is indicated as an adjunct to lifestyle intervention in patients with a BMI of 30 kg/m2 or above, or 27 kg/m2 or above with at least one weight-related comorbidity" [6]. Citing that guideline in an appeal letter provides clinical backing for coverage.

Clinical Efficacy: Why Florida Providers Prescribe Tirzepatide

Understanding cost in isolation from efficacy is not a complete picture for patients or prescribers. Tirzepatide's dual agonism at both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors gives it a distinct mechanism compared to semaglutide-only agents.

In SURPASS-2 (N=5,878), tirzepatide at 15 mg produced a 12.4 kg mean weight reduction and a 2.46 percentage-point HbA1c reduction over 40 weeks in adults with type 2 diabetes already on semaglutide 1 mg [1]. For obesity without diabetes, the SURMOUNT-1 trial (N=2,539) demonstrated a mean weight reduction of 20.9% at 72 weeks with tirzepatide 15 mg versus 3.1% with placebo (P<0.001) [7].

The Endocrine Society 2023 Obesity Pharmacotherapy Guidelines classify tirzepatide as a first-line pharmacotherapy option for obesity management given its efficacy profile, recommending initiation after a discussion of benefits, risks, and cost [8]. For Florida prescribers managing patients who cannot afford branded Mounjaro, the guidelines' explicit acknowledgment of cost barriers supports documenting an access-related rationale for compounded tirzepatide.

Navigating the Florida-Specific Regulatory Environment

Florida has no state law that restricts access to GLP-1 or dual GIP/GLP-1 medications beyond federal standards. However, three Florida-specific considerations affect access in practice:

Florida's 503A pharmacy board oversight is active. The Florida Department of Health's Board of Pharmacy conducts routine inspections of 503A compounding pharmacies and has issued cease-and-desist orders to at least two Florida facilities for non-sterile compounding practice violations since 2023. Patients should check the pharmacy's inspection status through the Florida Department of Health online verification portal before submitting a prescription.

Florida telehealth law requires synchronous evaluation for new prescriptions. While asynchronous (store-and-forward) telehealth is permitted in Florida for certain services, Florida Statute 456.44 requires a real-time, two-way audio-video interaction for prescribing medications to a new patient. Platforms that issue tirzepatide prescriptions based on questionnaires alone do not satisfy this requirement.

Florida does not restrict out-of-state mail-order pharmacy fulfillment for non-controlled medications. A Florida patient can legally receive compounded tirzepatide shipped from a 503A pharmacy licensed in another state, provided the originating pharmacy holds active licensure in its home state and the prescription was written by a Florida-licensed prescriber. The receiving pharmacy does not need a Florida dispensing license for non-controlled, patient-specific compounded medications, though many compliance-conscious platforms use Florida-licensed pharmacies exclusively.